Tilray Brands Rebrands Italian Medical Cannabis Unit to Expand European Footprint
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5d ago
0mins
Source: Benzinga
- Market Restructuring: Tilray Medical Italia replaces FL Group, marking a strategic reorganization in Italy's medical cannabis sector aimed at unifying compliance platforms across key European markets and enhancing brand influence.
- Product Diversification: The new entity will offer a range of medicines approved by Italy's health authorities, including high-THC flowers and THC-CBD oil, catering to diverse medical needs while ensuring compliance with strict EU-GMP standards.
- Partnership Enhancement: Collaboration with Molteni Farmaceutici will bolster Tilray's distribution capabilities in Italy, increasing physician engagement and ensuring responsible prescribing through hospitals, doctors, and pharmacies.
- Strategic Importance: Tilray emphasizes the significance of the Italian market, committing to building a leading medical cannabis platform in Europe while supporting compliance operations in over 20 countries and promoting evidence-based therapeutic solutions.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLRY is 9.57 USD with a low forecast of 8.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 8.730
Low
8.50
Averages
9.57
High
10.00
Current: 8.730
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.








